{"id":"placebo-for-hydrochlorothiazide","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL435","moleculeType":"Small molecule","molecularWeight":"297.75"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In this context, it serves as the control arm in a Phase 3 trial comparing the effects of hydrochlorothiazide against no active treatment.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:42.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 clinical trial for hydrochlorothiazide efficacy"}]},"trialDetails":[{"nctId":"NCT05373264","phase":"PHASE3","title":"HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-07-31","conditions":"ADPKD","enrollment":300},{"nctId":"NCT04676399","phase":"EARLY_PHASE1","title":"Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-02-08","conditions":"Chronic Pain, Hypertension, Diuretics Drug Reactions","enrollment":36},{"nctId":"NCT04654312","phase":"PHASE1","title":"Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)","status":"COMPLETED","sponsor":"Universität des Saarlandes","startDate":"2021-01-18","conditions":"Photosensitivity","enrollment":30},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT04934228","phase":"PHASE1","title":"Mitigating the Pro-inflammatory Phenotype of Obesity","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-07-01","conditions":"Blood Pressure, Diabetes, Obesity","enrollment":60},{"nctId":"NCT06681116","phase":"NA","title":"Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation","status":"COMPLETED","sponsor":"ALI KAMAL M. SAMI","startDate":"2015-02-16","conditions":"Renal Stones, Idiopathic Hypercalciuria","enrollment":325},{"nctId":"NCT05582837","phase":"PHASE4","title":"Treatment of Meniere's Disease With Migraine Medications","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-01","conditions":"Ménière","enrollment":100},{"nctId":"NCT00447603","phase":"PHASE3","title":"A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)","status":"TERMINATED","sponsor":"Organon and Co","startDate":"2007-05-24","conditions":"Hypertension","enrollment":40},{"nctId":"NCT01307046","phase":"PHASE3","title":"MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":336},{"nctId":"NCT01307033","phase":"PHASE3","title":"A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-03-29","conditions":"Hypertension","enrollment":278},{"nctId":"NCT03057431","phase":"PHASE3","title":"Hydrochlorothiazide for Kidney Stone Recurrence Prevention","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-03-09","conditions":"Nephrolithiasis","enrollment":416},{"nctId":"NCT03298802","phase":"PHASE3","title":"Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide","status":"UNKNOWN","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-11-21","conditions":"Pre-Eclampsia, Gestational Hypertension, Superimposed Pre-Eclampsia","enrollment":612},{"nctId":"NCT05443932","phase":"PHASE4","title":"Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2024-03-04","conditions":"Urolithiasis, Hyperoxaluria","enrollment":32},{"nctId":"NCT01983462","phase":"PHASE2","title":"Vascular Dysfunction in Human Obesity Hypertension","status":"TERMINATED","sponsor":"Gary L. Pierce","startDate":"2013-10","conditions":"Obesity, Prehypertension, Hypertension","enrollment":33},{"nctId":"NCT00289887","phase":"PHASE3","title":"Obese Hypertension Study (0954-315)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypertension","enrollment":261},{"nctId":"NCT03423355","phase":"PHASE4","title":"Dapagliflozin Effect on Erythropoiesis and Physical Fitness","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT03971929","phase":"PHASE1","title":"Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-07-31","conditions":"Hypertension","enrollment":36},{"nctId":"NCT02699125","phase":"PHASE4","title":"Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-01","conditions":"Obstructive Sleep Apnea","enrollment":41},{"nctId":"NCT02710071","phase":"PHASE4","title":"Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2015-01","conditions":"Hypertension","enrollment":41},{"nctId":"NCT04465123","phase":"PHASE3","title":"Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-08-13","conditions":"Acute Heart Failure, Acute Kidney Injury","enrollment":100},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03951558","phase":"NA","title":"Comparison of the Impact of Diet vs Thiazide in BMD in Children With Idiopathic Hypercalciuria","status":"UNKNOWN","sponsor":"Hospital Infantil de Mexico Federico Gomez","startDate":"2018-05-11","conditions":"Hypercalciuria; Idiopathic, Nephrolithiasis","enrollment":90},{"nctId":"NCT03658850","phase":"PHASE2","title":"Safety and Efficacy of Hydrochlorothiazide in the Treatment of Hypernatremia in Critically Ill Patients","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2018-10-01","conditions":"Hypernatremia, Critical Illness","enrollment":184},{"nctId":"NCT01302691","phase":"PHASE3","title":"MK-0954E Study in Participants With Hypertension (MK-0954E-357)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-01-01","conditions":"Hypertension","enrollment":327},{"nctId":"NCT00902538","phase":"PHASE3","title":"Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2009-04","conditions":"Essential Hypertension","enrollment":2204},{"nctId":"NCT00430950","phase":"PHASE3","title":"Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-02","conditions":"Essential Hypertension","enrollment":1011},{"nctId":"NCT00430508","phase":"PHASE3","title":"Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2007-02","conditions":"Essential Hypertension","enrollment":972},{"nctId":"NCT01838850","phase":"PHASE3","title":"Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","status":"COMPLETED","sponsor":"Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":344},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT00430638","phase":"PHASE4","title":"A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-12","conditions":"Hypertension","enrollment":278},{"nctId":"NCT01370655","phase":"PHASE1","title":"A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-15","conditions":"Hypertension","enrollment":46},{"nctId":"NCT01096667","phase":"PHASE2","title":"Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-17","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":194},{"nctId":"NCT00478335","phase":"NA","title":"Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":"Nephrogenic Diabetes Insipidus","enrollment":4},{"nctId":"NCT00168779","phase":"PHASE4","title":"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Hypertension","enrollment":1185},{"nctId":"NCT03276598","phase":"PHASE4","title":"A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"1999-11-25","conditions":"Hypertension, Pharmacogenetics","enrollment":233},{"nctId":"NCT03115853","phase":"PHASE4","title":"The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2009-06","conditions":"High Blood Pressure","enrollment":31},{"nctId":"NCT00865124","phase":"NA","title":"Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2008-09","conditions":"Type 2 Diabetes Mellitus, Vascular Disease","enrollment":69},{"nctId":"NCT02738632","phase":"PHASE3","title":"Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":300},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT00806585","phase":"PHASE2","title":"Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":620},{"nctId":"NCT00886600","phase":"PHASE3","title":"A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1991-05","conditions":"Hypertension","enrollment":122},{"nctId":"NCT00871871","phase":"PHASE1","title":"Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Hypertension","enrollment":64},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01822860","phase":"PHASE4","title":"Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2013-03","conditions":"Hypertension","enrollment":""},{"nctId":"NCT01259297","phase":"PHASE3","title":"A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Cardiovascular Events","enrollment":2336},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT00775814","phase":"PHASE4","title":"Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2006-10","conditions":"Obesity, Hypertension","enrollment":188},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT01138423","phase":"PHASE4","title":"Treatment of Adiposity Related hypErTension (TARGET)","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2010-08","conditions":"Hypertension, Abdominal Obesity, Metabolic Syndrome","enrollment":32},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00765674","phase":"PHASE3","title":"Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-09","conditions":"Hypertension","enrollment":1191},{"nctId":"NCT00185172","phase":"PHASE3","title":"Olmesartan in Essential Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2002-01","conditions":"Essential Hypertension","enrollment":2333},{"nctId":"NCT00214825","phase":"NA","title":"Aldosterone and Vascular Disease in Diabetes Mellitus","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2003-08","conditions":"Diabetes Mellitus, Endothelial Dysfunction, Albuminuria","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1071,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Hydrochlorothiazide","genericName":"Placebo for Hydrochlorothiazide","companyName":"IlDong Pharmaceutical Co Ltd","companyId":"ildong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial for hydrochlorothiazide efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}